三种不同聚合物涂层雷帕霉素洗脱支架治疗冠心病患者的十年临床结局:一项随机试验
该随机试验纳入2603例冠心病患者,比较生物可降解聚合物西罗莫司洗脱支架(BP-SES)、永久聚合物依维莫司洗脱支架(PP-EES)与早期永久聚合物西罗莫司洗脱支架(PP-SES)的10年结局。主要终点为主要不良心血管事件(MACE),BP-SES与PP-EES的10年MACE和死亡率无显著差异,而PP-SES的MACE和明确支架内血栓发生率更高。
要点
- BP-SES与PP-EES在10年MACE和死亡率上无显著差异。
- PP-SES的10年MACE和明确支架内血栓发生率显著高于BP-SES和PP-EES。
- 明确/可能支架内血栓在三组间无显著差异。
核心结论
- BP-SES与PP-EES在10年临床结局上相当。
- PP-SES的MACE和明确支架内血栓发生率更高。
研究设计与样本
- 随机对照试验,纳入2603例冠心病患者,随机分为BP-SES组(n=1299)、PP-EES组(n=652)和PP-SES组(n=652)。
- 主要终点为MACE(死亡、心肌梗死或靶病变血运重建的复合终点),次要终点为明确/可能支架内血栓。
- 10年随访率为83%。
主要发现
- 10年MACE发生率:BP-SES 47.7% vs PP-EES 46.0% vs PP-SES 54.9%(P=0.003)。
- 10年死亡率:BP-SES 31.8% vs PP-EES 30.3% vs PP-SES 37.2%(P=0.02)。
- 明确/可能支架内血栓发生率:BP-SES 1.8% vs PP-EES 2.5% vs PP-SES 3.7%(P=0.09)。
- 明确支架内血栓发生率:BP-SES 1.1% vs PP-EES 0.8% vs PP-SES 2.4%(P=0.03)。
- BP-SES与PP-EES之间无显著差异。
临床怎么用
- 在冠心病介入治疗中,BP-SES与PP-EES的10年结局相当,均可作为选择。
- PP-SES的长期MACE和明确支架内血栓风险较高,支持优先选用新型药物洗脱支架。
局限性
- 10年随访率仅为83%,存在失访偏倚可能。
- PP-EES和PP-SES组样本量较小(各652例),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New-generation drug-eluting stents offer the potential for enhanced late outcomes in comparison with early generation drug-eluting stents. However, assessment of extended long-term outcomes for these devices is lacking, especially regarding the comparison between new-generation drug-eluting stents with biodegradable or permanent polymers. The aim of this study is to compare the efficacy and safety of biodegradable polymer-based sirolimus-eluting stents (BP-SES; Yukon Choice PC) versus permanent polymer-based everolimus-eluting stents (PP-EES; Xience) versus early generation permanent polymer-based sirolimus-eluting stents (PP-SES; Cypher) at 10-year follow-up. METHODS: Overall, 2603 patients were randomized to treatment with BP-SES (n=1299), PP-EES (n=652), or PP-SES (n=652). The primary end point of this analysis was major adverse cardiac event, the composite of death, myocardial infarction, or target lesion revascularization. The main secondary end point of interest was definite/probable stent thrombosis. Follow-up at 10 years was available in 83% of the study patients. RESULTS: The 10-year incidence of major adverse cardiac event (BP-SES 47.7% versus PP-EES 46.0% versus PP-SES 54.9%, P=0.003) and mortality (BP-SES 31.8% versus PP-EES 30.3% versus PP-SES 37.2%, P=0.02) was different among the groups. Definite/probable stent thrombosis was not significantly different among the groups (BP-SES 1.8% versus PP-EES 2.5% versus PP-SES 3.7%, P=0.09). Definite stent thrombosis was significantly different among the groups (BP-SES 1.1% versus PP-EES 0.8% versus PP-SES 2.4%, P=0.03). There were no significant differences between BP-SES and PP-EES. CONCLUSIONS: In this unique long-term outcome analysis, BP-SES and PP-EES showed comparable clinical outcomes out to 10 years. PP-SES had higher rates of major adverse cardiac events and definite stent thrombosis. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00598676.
引用
- Kufner S, Joner M, Thannheimer A, et al. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Circulation. 2019. PMID: 30586724. doi:10.1161/CIRCULATIONAHA.118.038065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。